Benzinga

Benzinga

Benzinga

martes, septiembre 01

Ascendis Pharma AS

ASNDNASDAQ
Trade with Public
Trade with Public
$263.04
15.136.1%
al cierre: Aug 28, 5:00 PM EST
$264.25
16.346.59%
Premercado: 7:00 AM EST
PRO
¿Por qué se mueve?:Ascendis Pharma shares are trading higher after BioMarin granted the compan...
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararOpcionesInforme de acciones

Ascendis Pharma Analyst Price Targets

Wall Street analyst price targets and consensus rating for Ascendis Pharma (ASND).

Price Target Range — 10 Quarters

Analyst Consensus — 19 Analysts

1S.Buy
18Buy
Consensus RatingBuy# Analysts19Avg. Consensus PT$294Upside to Avg. PT+11.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 31, 2026B of A SecuritiesTazeen AhmadPT CutBuy$306→$304
Aug 31, 2026JefferiesKelly ShiPT CutBuy$333→$330
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
B of A Securities Maintains Buy on Ascendis Pharma, Lowers Price Target to $304

B of A Securities analyst Tazeen Ahmad maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and lowers the price target from $306 to $304.
Benzinga Newsdesk

PRO
Jefferies Maintains Buy on Ascendis Pharma, Lowers Price Target to $330

Jefferies analyst Kelly Shi maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and lowers the price target from $333 to $330.
Benzinga Newsdesk

PRO
Stifel Maintains Buy on Ascendis Pharma, Lowers Price Target to $326

Stifel analyst Alex Thompson maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and lowers the price target from $328 to $326.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Ascendis Pharma, Lowers Price Target to $344

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and lowers the price target from $345 to $344.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Ascendis Pharma, Maintains $345 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Ascendis Pharma (NASDAQ:ASND) with a Buy and maintains $345 price target.
Benzinga Newsdesk

This Ascendis Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday

Analysts initiate coverage and change ratings on top stocks like ASND, DOCN, ODTX, MT, and NVCT. See their price targets and views on these stocks.
Avi Kapoor

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Datos de mercado proporcionados por APIs de Benzinga

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved